Terapevticheskii arkhiv · 1998
[Heptral potentialities in the treatment of hepatic damage in children with malignant blood disease].
Клинический случайСравнительное исследованиеАннотация на английскомСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reĭzis A R, Nurmukhametova E A
Аннотация
AIM: To assess benefit for children with malignant blood disease (MBD) of the hepatoprotector heptral.
MATERIALS AND METHODS: 67 children with blood malignancy aged 3-14 years were examined (53 of them had acute lymphoblastic leukemia). 39 patients were in the study group (25 of them had hepatitis B or C), 28 were controls. Initially, heptral was injected intravenously (14 days) then orally (16-30 days). Activity of transaminases and number of violations of polychemotherapy protocols because of hepatic toxicity were registered.
RESULTS: Heptral administration led to inhibited activity of AlAT and AsAT especially in non-infected patients. Protocol deviations became less frequent.
CONCLUSION: Heptral is a potent hepatoprotector in hepatic lesions of toxic, viral and mixed origin.
MATERIALS AND METHODS: 67 children with blood malignancy aged 3-14 years were examined (53 of them had acute lymphoblastic leukemia). 39 patients were in the study group (25 of them had hepatitis B or C), 28 were controls. Initially, heptral was injected intravenously (14 days) then orally (16-30 days). Activity of transaminases and number of violations of polychemotherapy protocols because of hepatic toxicity were registered.
RESULTS: Heptral administration led to inhibited activity of AlAT and AsAT especially in non-infected patients. Protocol deviations became less frequent.
CONCLUSION: Heptral is a potent hepatoprotector in hepatic lesions of toxic, viral and mixed origin.